Our mission
To contribute to the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.
Cergentis to advance TLA-based targeted complete next generation sequencing for cancer companion diagnostics.
Uniquely, TLA enables targeted, complete, cost-effective Next Generation Sequencing
Cergentis provides services and kits for targeted NGS sequencing of any (trans)gene of interest
"TLA is a highly efficient method for mapping the insertion site of any transgene.”
Søren Warming Ph.D.(Senior Scientist Genentech, San Francisco, USA)"The main advantage of TLA over conventional approaches is that it generates complete sequence information of a region of interest."
Taconic"TLA outperforms traditional methods used in CHO cell-line characterisation and provides higher resolution and sensitivity.”
Stefanie Bartels Ph.D.(Synthon, the Netherlands)"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”
Prof. Joshua Sanes(Harvard University, Department of Molecular and Cellular Biology, USA)"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”
Alfredo Brusco Ph.D.(Department of Medical Sciences, University of Turin, Italy)"Unlike other targeted sequencing methods, TLA works without detailed prior locus information, as one primer pair is sufficient to amplify and sequence tens to hundreds of kilobases of surrounding DNA.”
Pacific Biosciences"We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”
Roland Kuiper Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)"TLA has proven to be a powerful technology for transgene integration site sequencing and for evaluation of structural changes in the transgene and/or integration site.”
Nik Klymiuk Ph.D.(Faculty Veterinary Science Ludwig Maximilians University Munich, Germany)"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”
Jules Meijerink Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”
Pieter van Vlierberghe Ph.D.(Center for Medical Genetics, Ghent University, Belgium)Blog:
"Targeted Locus Amplification (TLA), a comprehensive method of selectively amplifying genes and detecting all variation within, while preserving haplotype information.”
"TLA analysis has proven to be very useful to quality control genetically engineered cell-lines”
John Wiseman Ph.D.(AstraZeneca, Mölndal, Sweden)To contribute to the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.